Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Keytruda’s November Listing Skip Likely amid Opdivo Re-Pricing Fuss
MSD’s immuno-oncology drug Keytruda (pembrolizumab) is expected to skip the upcoming round of reimbursement listing in November amid continued uncertainties over the re-pricing of rival med Opdivo (nivolumab), sources familiar with the matter told Jiho. Keytruda was approved in September…
To read the full story
Related Article
- MSD to Seek Keytruda Listing after Adding Lung Cancer Indication
November 10, 2016
- Policymakers Face Balancing Act over Opdivo Re-Pricing
October 17, 2016
REGULATORY
- Finance Minister Backs Further Debate on Low-Risk Medicines: CEFP Minutes
May 29, 2026
- LDP HQ Finalizes Recommendations ahead of Growth Strategy
May 29, 2026
- Japan Eyes Broader Healthcare Measures Addressing Sex-Based Health Issues
May 28, 2026
- MHLW Panel Deems 4 More “Drug Loss” Products as High-Need
May 27, 2026
- LDP Panel OKs Immunization Act Bill Aimed at Beyfortus NIP Use
May 27, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…